Continuous renal replacement therapy in COVID-19—associated AKI: adding heparin to citrate to extend filter life—a retrospective cohort study

Table 2 Adverse events in patients undergoing continuous renal replacement therapy, by anticoagulation strategy

Event	COV −	COV +		p	p*
	ACD-A only	ACD-A only	ACD-A + UH
	(n = 50)	(n = 64)	(n = 124)
Minor bleeding episode,^a %	8.0	1.7	4.2	0.319	0.665
Major bleeding episode,^a %	16.0	5.0	5.0	0.060	1.000
Blood transfusion, %	44.0	23.4	25.0	0.024	0.954
Platelet count < 100,000,^b %	42.0	20.3	13.4	< 0.001	0.335
Peak aPTT in the first 72 h of CRRT^c, median (IQR)	1.14 (1.01–1.64)	1.30 (1.10–1.69)	2.42 (1.70–3.52)	< 0.001	< 0.001
In-hospital mortality, %	64.0	84.4	84.7	0.005	1.000
Hypokalemia,^d %	16.3	10.3	10.8	0.556	1.000
Hyperkalemia,^e %	16.0	6.4	12.4	0.269	0.482
Hypophosphatemia,^c %	20.5	13.2	19.8	0.548	0.742
Hyperphosphatemia,^f %	15.2	9.7	18.5	0.304	0.560
Hyponatremia,^g %	6.0	0.0	1.8	0.077	0.549
Hypernatremia,^h %	2.0	1.8	0.9	0.791	1.000
Hypocalcemia,ⁱ %	28.3	29.0	22.5	0.559	0.849
Hypercalcemia,^j %	25.5	20.3	12.3	0.099	0.356
Alkalosis,^k %	35.4	17.0	17.7	0.028	1.000
Acidosis,^e %	14.3	12.9	13.9	0.974	1.000

COV−, not diagnosed with coronavirus disease 2019; COV+, diagnosed with coronavirus disease 2019; ACD-A, anticoagulant citrate dextrose solution formula A; UH, unfractionated heparin; aPTT, activated partial thromboplastin time, IQR, interquartile range; CRRT, continuous renal replacement therapy
^an = 229; ^bn = 221; ^cn = 193; ^dn = 218, ^en = 233, ^fn = 216, ^gn = 215, ^hn = 219, ⁱn = 228, ^jn = 220, ^kn = 214
*Kruskal–Wallis for COV + ACD-A only vs. COV + ACD-A + UH

ISSN: 1364-8535